{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:57:36Z","timestamp":1754488656148},"reference-count":8,"publisher":"American Diabetes Association","issue":"10","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"DOI":"10.2337\/db13-0690","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T11:30:55Z","timestamp":1380108655000},"page":"e16-e17","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":11,"title":["Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595\u20132604"],"prefix":"10.2337","volume":"62","author":[{"given":"Robert J.","family":"Heine","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories and Lilly Diabetes, Eli Lilly & Co., Indianapolis, Indiana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoda","family":"Fu","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories and Lilly Diabetes, Eli Lilly & Co., Indianapolis, Indiana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Kendall","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories and Lilly Diabetes, Eli Lilly & Co., Indianapolis, Indiana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Moller","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories and Lilly Diabetes, Eli Lilly & Co., Indianapolis, Indiana."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2013,9,17]]},"reference":[{"key":"2022031211141252000_B1","author":"Butler"},{"key":"2022031211141252000_B2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.pas.0000180440.41280.a5","article-title":"The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms","volume":"30","author":"Stelow","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2022031211141252000_B3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00428-005-0032-1","article-title":"Pancreatic fibrosis associated with age and ductal papillary hyperplasia","volume":"447","author":"Detlefsen","year":"2005","journal-title":"Virchows Arch"},{"key":"2022031211141252000_B4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/db09-1698","article-title":"\u03b2-cell replication is increased in donor organs from young patients after prolonged life support","volume":"59","author":"In\u2019t Veld","year":"2010","journal-title":"Diabetes"},{"key":"2022031211141252000_B5","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model","volume":"61","author":"Gier","year":"2012","journal-title":"Diabetes"},{"key":"2022031211141252000_B6","doi-asserted-by":"crossref","first-page":"E1076","DOI":"10.1152\/ajpendo.00479.2010","article-title":"Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents","volume":"299","author":"Tatarkiewicz","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031211141252000_B7","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1152\/ajpendo.00182.2012","article-title":"The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis","volume":"303","author":"Vrang","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031211141252000_B8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dom.12040","article-title":"No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks","volume":"15","author":"Tatarkiewicz","year":"2013","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/62\/10\/e16\/570528\/e16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/62\/10\/e16\/570528\/e16.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:37:03Z","timestamp":1667407023000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/62\/10\/e16\/17741\/Comment-on-Butler-et-al-Marked-Expansion-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,17]]},"references-count":8,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,9,17]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db13-0690","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,17]]}}}